- CA$43.32m
- CA$66.25m
- CA$17.75m
- 13
- 52
- 36
- 24
Annual income statement for LSL Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2012 July 31st | 2021 July 31st | 2022 July 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 15 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 10 | 17.7 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | 1.65 | 5.35 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.88 | 0.091 | 0.074 | 14.6 | 12.1 |
| Operating Profit | -1.88 | -0.091 | -0.074 | -4.55 | 5.69 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.88 | -0.091 | -0.074 | -8.47 | 3.37 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.83 | -0.091 | -0.074 | -8.47 | 3.32 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.83 | -0.091 | -0.074 | -8.47 | 3.32 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.83 | -0.091 | -0.074 | -8.47 | 3.32 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.84 | -0.11 | -0.09 | -0.074 | 0.001 |
| Dividends per Share |